Browsing by Author "Gortari, Jose Ignacio"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings
    (2024) Pestchanker, Claudia; Cortez, Brenda Bertado; Peixoto, Marco A. Lana; Gortari, Jose Ignacio; Suarez, Sheila Castro; Zamalloa, Cesar Caparo; Galiana, Graciana; Penalver, Francisco; Marques, Vanesa Daccach; Messias, Katharina; Galleguillos, Lorna; Garcia, Fernando; Rojas, Juan I.; Patrucco, Liliana; Cristiano, Edgardo; Tkachuk, Veronica; Liwacki, Susana; Correale, Jorge; Marrodan, Mariano; Ysraelit, Maria C.; Vrech, Carlos; Deri, Norma; Leguizamon, Felisa; Tavolini, Dario; Mainella, Carolina; Zanga, Gisela; Serena, Marina Alonso; Ciampi, Ethel; Soares Neto, Herval Ribeiro; Lopez, Pablo; Contentti, Edgar Carnero
    IntroductionWe aimed to assess the frequency, duration, and severity of area postrema syndrome (APS) during follow-up in neuromyelitis optica spectrum disorder (NMOSD) patients, as well as its association with inflammatory activity and prognostic factors of APS severity in a real-world setting.MethodsWe conducted a retrospective study on a cohort of Latin American (LATAM) NMOSD patients who had experienced APS during their follow-up. Patients from Mexico, Peru, Brazil, Colombia, Panama, Chile and Argentina patients who met 2015 NMOSD criteria were included. We evaluated data on symptom type (nausea, vomiting and/or hiccups), frequency, duration, severity (measured by APS severity scale), association with other NMOSD core relapses, and acute treatments (symptomatic and immunotherapy or plasmapheresis). Logistic regression was conducted to evaluate factors associated with APS severity (vs. mild-moderate).ResultsOut of 631 NMOSD patients, 116 (18.3%) developed APS during their follow-up. The most common APS phenotype was severe. Inflammatory activity (i.e., relapses) significantly decreased after the onset of APS. Half of the patients experienced isolated APS with a median duration of 10 days, and the most frequently used acute treatment was IV steroids. All three symptoms were present in 44.6% of the patients. APS symptoms resolved following immunotherapy. Logistic regression did not identify independent factors associated with the severity of APS.ConclusionsOur findings indicate that 18.3% of NMOSD patients developed APS during the follow-up period, with most patients fulfilling criteria for severe APS. The inflammatory activity decreased after the onset of APS compared to the previous year.
  • No Thumbnail Available
    Item
    The real-world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody-associated disease criteria in a Latin American cohort
    (2024) Contentti, Edgar Carnero; Pestchanker, Claudia; Ciampi, Ethel; Suarez, Sheila Castro; Zamalloa, Cesar Caparo; Marques, Vanesa Daccach; Messias, Katharina; Gortari, Jose Ignacio; Tkachuk, Veronica; Silva, Berenice; Mainella, Carolina; Reyes, Saul; Toro, Jaime; Rodriguez, Juan; Correa-Diaz, Edgar; Rojas, Juan I.; Paul, Friedemann
    Background and Purpose: The diagnostic criteria for myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated disease (MOGAD) were published in 2023. We aimed to determine the performance of the new criteria in Latin American (LATAM) patients compared with the 2018 criteria and explore the significance of MOG-IgG titers in diagnosis. Methods: We retrospectively reviewed the medical records of LATAM (Argentina, Chile, Brazil, Peru, Ecuador, and Colombia) adult patients with one clinical MOGAD event and MOG-IgG positivity confirmed by cell-based assay. Both 2018 and 2023 MOGAD criteria were applied, calculating diagnostic performance indicators. Results: Among 171 patients (predominantly females, mean age at first attack = 34.1 years, mean disease duration = 4.5 years), 98.2% patients met the 2018 criteria, and of those who did not fulfill diagnostic criteria (n = 3), all tested positive for MOG-IgG (one low-positive and two without reported titer). Additionally, 144 (84.2%) patients met the 2023 criteria, of whom 57 (39.5%) had MOG-IgG+ titer information (19 clearly positive and 38 low-positive), whereas 87 (60.5%) patients had no MOG-IgG titer. All 144 patients met diagnostic supporting criteria. The remaining 27 patients did not meet the 2023 MOGAD criteria due to low MOG-IgG (n = 12) or lack of titer antibody access (n = 15), associated with the absence of supporting criteria. The 2023 MOGAD criteria showed a sensitivity of 86% (95% confidence interval = 0.80-0.91) and specificity of 100% compared to the 2018 criteria. Conclusions: These findings support the diagnostic utility of the 2023 MOGAD criteria in an LATAM cohort in real-world practice, despite limited access to MOG-IgG titration.